NCT02608437View on ClinicalTrials.gov

A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients

PHASE1UnknownINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2018

Conditions
Metastatic Melanoma
Interventions
DRUG

SGI-110

SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2

DRUG

Ipilimumab

ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.

Trial Locations (1)

53100

RECRUITING

Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

Italian Network for Tumor Biotherapy Foundation

OTHER